TrialBMC urology2023

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).

Soichiro Yoshida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.